Great Western Exploration Limited

GTE

Great Western Exploration Ltd. engages in the exploration of gold and base metals deposits in Australia. The company is headquartered in Perth, Western Australia. The company went IPO on 2007-06-05. Its projects include Yerrida North - Oval and Oval South, Fairbairn Copper Project, Lake Way Potash, Firebird Gold Project, Golden Corridor, Yandal West, Yerrida South and Atley Gold. The Firebird Gold Project is located within the Youanmi Greenstone Belt, comprised of 100% owned GTE tenure and the adjacent Great Western-Dynamic Metals Joint Venture (Great Western earning 80%). The Yerrida North Project is located on the northern and western portions of the Yerrida Basin, approximately 800 km north-east of Perth and adjacent to the DeGrussa and Monty Cu-Au Volcanic Hosted Massive Sulphide deposits. The Fairbairn Copper Project is located 900 km north-east of Perth and 120 km from Sandfire Resources' DeGrussa copper-gold project. Its 100% owned Golden Corridor Project covers the northern extension of the Wiluna-Norseman Greenstone Belt.

Genetic Technologies Limited

GTG

Genetic Technologies Ltd. operates as a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. The company is headquartered in Melbourne, Victoria and currently employs 60 full-time employees. The firm is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The firm offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The firm has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The firm operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor

Great Southern Mining Limited

GSN

Great Southern Mining Ltd. is a mineral exploration company, which engages in the exploration and evaluation of economic deposits for gold and other minerals. The company is headquartered in Balcatta, Western Australia. The company went IPO on 2011-04-14. The firm's projects are located within approximately 25 kilometers (km) of operating mills and major operations. The Southern Star project is located approximately four km along strike to the south of the Ben Hur Deposit and 32 km south of the Garden Well Mill. The Mon Ami Project comprises a mining lease M38/1256 granted. The tenement lies within the Mt Margaret Mineral Field of the north-eastern Goldfields of Western Australia (Laverton Greenstone Belt), approximately 14 km east of the Granny Smith Mill and 12 km southeast of Laverton. The Edinburgh Park project is a greenfield exploration project, which comprises seven exploration permits for minerals. The project is located approximately 100 km southeast of Townsville in northern Queensland. The East Laverton Project is dominated by the Diorite Hill Layered Ultramafic Magmatic Intrusion, which covers an area of approximately 110 square kilometers.

Genetic Signatures Limited

GSS

Genetic Signatures Ltd. is a research company, which engages in the identification and commercialization of individual genetic signatures for the diagnosis of infectious diseases. The firm's principal activities include research and commercialization of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces. The firm is focused on the development and commercialization of its platform technology, 3base. Its MDx 3base platform technology provides high-volume hospitals and pathology laboratories with the ability to screen for an array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. The company designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen brand. Its products include EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, EasyScreen Viral Meningitis Detection Kit, and others.